Jyong Biotech Ltd. (MENS)
MENS trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | MENS on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Taiwan |
| IPO year | 2025 |
| SEC CIK | 0001954488 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | Cayman Islands |
Financials
Foreign filer: no machine-readable annual figure in SEC data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "We concluded that there is substantial doubt about our ability to continue as a going concern for a period of one year from the date that the unaudited interim consolidated financial statements included in this registration statement were issued." | 20-F 2026-05-15 |
| Cash and burn | $1.2M cash; operating cash flow -$760K a quarter. | Report 2025-12-31 |
| Shares outstanding | 76,027,667 (2025-12-31). the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures. | Cover page 2025-12-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | WWC, P.C., San Mateo, California, United States | PCAOB Form AP 2026-05-15 |
| Late filings, 12 months | 1 NT notice | NT 20-F 2026-04-29 |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | Not filed | -$4.7M | -$3.0M | $1.2M | $17.5M | Needs four quarters | 20-F 2026-05-15 |
| FY 2024 2024-12-31 | Not filed | -$3.0M | -$3.6M | $101K | No debt tags | Needs four quarters | 20-F 2026-05-15 |
| FY 2023 2023-12-31 | Not filed | -$4.4M | -$2.6M | $1.7M | No debt tags | Needs four quarters | 20-F 2026-05-15 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document PROSPECTUS | 424B4 | 2025-06-18 |
| Latest annual report ANNUAL REPORT | 20-F | 2026-05-15 |
| Latest quarterly / interim REPORT OF FOREIGN PRIVATE ISSUER | 6-K | 2026-02-06 |
Source: SEC EDGAR submissions feed, 73 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -2.2% |
| 1 month | -13.7% |
| 3 months | -14.6% |
| Year to date | -55.4% |
| 1 year | -95.4% |
| From 52-week high | -95.4% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| MSLE | Satellos Bioscience Inc. | $6.47 | -2.34% | $137.3M |
| NTHI | NeOnc Technologies Holdings Inc. | $4.54 | -7.54% | $131.0M |
| CNTN | Canton Strategic Holdings Inc. | $1.64 | -4.09% | $130.7M |
| MGNX | MacroGenics Inc. | $2.17 | -1.36% | $138.7M |
| RNA | Atrium Therapeutics Inc. | $6.43 | -14.38% | $138.7M |
| SION | Sionna Therapeutics Inc. | $3.12 | -6.31% | $141.1M |
| ALXO | ALX Oncology Holdings Inc. | $1.00 | -3.85% | $124.9M |
| AKBA | Akebia Therapeutics Inc. | $0.4486 | -5.40% | $124.6M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier